Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System

NACompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

September 30, 2015

Conditions
SyncopeRecurrent Symptomatic Atrial Fibrillation
Interventions
DEVICE

Insertable Cardiac Monitor Implant

The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.

Trial Locations (16)

3050

Royal Melbourne Hospital, Melbourne

4032

The Prince Charles Hospital, Brisbane

5000

Royal Adelaide Hospital, Adelaide

Unknown

Allgemein öffentliches Krankenhaus der Elisabethinen Linz, Linz

Allgemeines Krankenhaus der Stadt Linz, Linz

UZ Leuven - Campus Gasthuisberg, Leuven

CHU UCL Mont-Godinne - Dinant, Yvoir

Catharina Ziekenhuis, Eindhoven

Academisch Ziekenhuis Maastricht, Maastricht

St. Antonius Ziekenhuis - Locatie Nieuwegein, Nieuwegein

Diakonessenhuis Locatie Utrecht, Utrecht

Isala Klinieken - Locatie Weezenlanden, Zwolle

Scientific Research Institute of Circulation's Pathology Agency on High Medical Technologies, Novosibirsk

Narodny ustav srdcovych a cievnych chorob, a.s. (NUSCH), Bratislava

Eastbourne District General Hospital, Eastbourne

James Cook University Hospital, Middlesbrough

All Listed Sponsors
lead

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

NCT01965899 - Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System | Biotech Hunter | Biotech Hunter